Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluticasone Propionate Inhalation Powder in Healthy Volunteers
NCT05397834Phase 1Unknown
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate nasal spray in asthma (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Timepoint. Status: unknown.
02
Drugs
fluticasone propionate nasal spray
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05397834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397834.